Hepatitis C Infection Associated with Acquired Pure Red Cell Aplasia.

HCV bone marrow failure syndromes pure red cell aplasia

Journal

Tropical medicine and infectious disease
ISSN: 2414-6366
Titre abrégé: Trop Med Infect Dis
Pays: Switzerland
ID NLM: 101709042

Informations de publication

Date de publication:
22 Dec 2022
Historique:
received: 04 10 2022
revised: 13 12 2022
accepted: 15 12 2022
entrez: 20 1 2023
pubmed: 21 1 2023
medline: 21 1 2023
Statut: epublish

Résumé

Acquired pure red cell aplasia is a rare bone marrow failure disorder characterized by many underlying etiologies. The hallmark bone marrow feature is the near absence of erythroid precursors that otherwise exhibit normal cellularity, which has been attributed to both immune- and cellular-mediated mechanisms. Besides being merely speculative and considering the rarity of the disorder, the description of acquired pure red cell aplasia clinical associations represents a unique occasion to improve our current clinical knowledge of the disease, reveal clues on its pathogenesis, and guide therapeutic decisions. The varied clinical scenarios and common acquired pure red cell aplasia associated conditions (i.e., thymoma, T cell/NK-cell large granular lymphocyte leukemia, B cell dyscrasia) suggest a heterogeneity of pathogenic routes. Viral etiologies must always be considered and worked up in the initial assessment of newly diagnosed acquired pure red cell aplasia patients. In this report, we present two cases of hepatitis-C-related acquired pure red cell aplasia and successful use of anti-viral strategies in the achievement of a complete response.

Identifiants

pubmed: 36668915
pii: tropicalmed8010008
doi: 10.3390/tropicalmed8010008
pmc: PMC9862157
pii:
doi:

Types de publication

Case Reports

Langues

eng

Subventions

Organisme : National Institute of Health
ID : R35HL135795

Références

Blood. 2016 Nov 24;128(21):2504-2509
pubmed: 27881371
Hepatology. 1996 Aug;24(2):289-93
pubmed: 8690394
Blood. 2021 Apr 15;137(15):2001-2009
pubmed: 33657207
Medicine (Baltimore). 2003 Mar;82(2):87-96
pubmed: 12640185
Rinsho Ketsueki. 2009 May;50(5):424-9
pubmed: 19483404
Blood. 2020 Sep 10;136(11):1262-1273
pubmed: 32702755
Am J Gastroenterol. 1994 Feb;89(2):257-62
pubmed: 8304314
Blood Cells Mol Dis. 2021 Nov;91:102595
pubmed: 34280665
Leukemia. 2021 Jun;35(6):1792-1796
pubmed: 33414481
Haematologica. 2018 Feb;103(2):221-230
pubmed: 29217782
N Engl J Med. 1982 May 27;306(21):1254-8
pubmed: 6803159

Auteurs

Destini Teague (D)

Division of Hematology-Oncology, UT Southwestern Medical Center, Dallas, TX 75390, USA.

Carmelo Gurnari (C)

Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH 44195, USA.
Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.

Hussein Awada (H)

Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH 44195, USA.

Jaroslaw P Maciejewski (JP)

Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH 44195, USA.

Ibrahim Ibrahim (I)

Division of Hematology-Oncology, UT Southwestern Medical Center, Dallas, TX 75390, USA.

Taha Bat (T)

Division of Hematology-Oncology, UT Southwestern Medical Center, Dallas, TX 75390, USA.

Classifications MeSH